Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Change in Account Payables (2024 - 2026)

Evommune (EVMN) reported Change in Account Payables of -$3.7 million for Q1 2026, down 442.55% year-over-year from $1.1 million in Q1 2025, and down 197.35% on a QoQ basis from $3.9 million in Q4 2025.

Evommune (EVMN) has 3 years of Change in Account Payables data on file, last reported at -$3.7 million in Q1 2026.

  • Quarterly Change in Account Payables fell 442.55% year-over-year to -$3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (changed N/A YoY) and the FY2025 annual result came in at -$837000.0, down 112.87% from the prior year.
  • Change in Account Payables fell to -$3.7 million in Q1 2026 per EVMN's latest filing, from $3.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $3.9 million in Q4 2025 and bottomed at -$3.7 million in Q1 2026.
  • The 3-year median for Change in Account Payables is $1.1 million (2024), against an average of $566250.0.
  • The widest annual swing landed in 2025, when Change in Account Payables jumped 34.93%; it then sank 442.55% in 2026.
  • Tracing EVMN's Change in Account Payables over 3 years: stood at $2.9 million in 2024, then surged by 34.93% to $3.9 million in 2025, then tumbled by 197.35% to -$3.7 million in 2026.
  • Per Business Quant, the three latest EVMN Change in Account Payables figures stand at -$3.7 million (Q1 2026), $3.9 million (Q4 2025), and -$691000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -3.26 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 35.60 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Evommune 782.16 Mn 570.69 Mn - -3.75 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -3.75 Mn
Mar 31, 2026 -3.75 Mn
Dec 31, 2025 3.85 Mn
Dec 31, 2025 3.85 Mn
Mar 31, 2025 -691,000.00
Mar 31, 2025 -691,000.00
Dec 31, 2024 2.85 Mn
Dec 31, 2024 2.85 Mn